Loading...
Silence Therapeutics Q1 2025 Earnings Report
Silence Therapeutics reported its financial results for the first quarter ended March 31, 2025, highlighting strong clinical and operational execution, extended cash guidance, and advancements in its siRNA programs.
Key Takeaways
Silence Therapeutics reported a net loss of $28.5 million for Q1 2025, with revenues of $0.142 million. The company ended the quarter with $136.5 million in cash, cash equivalents, and short-term investments, and extended its cash guidance into 2028 through cost-saving initiatives.
Advanced patient enrollment into the SANRECO Phase 2 study of divesiran for Polycythemia Vera (PV), remaining on-track to complete enrollment by year-end 2025.
Additional Phase 1 results from the SANRECO study of divesiran in PV patients accepted for oral presentation at the European Hematology Association (EHA) 2025 Annual Congress.
Ended the first quarter with $136.5 million in cash, cash equivalents, and short-term investments.
Implemented cost savings initiatives and extended cash guidance into 2028.
Silence Therapeutics
Silence Therapeutics
Forward Guidance
Silence Therapeutics has extended its cash runway into 2028 by implementing cost savings initiatives, while remaining committed to advancing its core PV program and realizing the potential of its mRNAi GOLD™ platform.
Positive Outlook
- On-track to complete enrollment for SANRECO Phase 2 study of divesiran by year-end 2025.
- Advanced core Phase 3 readiness activities for zerlasiran, including manufacturing and supply scale up, on-track to complete by mid-2025.
- Ongoing partnering discussions for potential Phase 3 development of zerlasiran.
- Continued investment in areas that enhance value to Silence stakeholders.
- Commitment to realizing the vast potential of the proprietary mRNAi GOLD™ platform.
Challenges Ahead
- No specific negative forward guidance was provided in the report.
- The company continues to incur net operating losses.
- The company's ability to obtain necessary capital to fund its clinical programs is a continuous consideration.
- The early stages of clinical development for product candidates present inherent risks.
- The company's reliance on third-party suppliers and manufacturers could pose risks.